Literature DB >> 28802227

Anti-inflammatory effects of Shufengjiedu capsule for upper respiratory infection via the ERK pathway.

Yanmei Li1, Nianwei Chang2, Yanqi Han3, Mengge Zhou1, Jie Gao1, Yuanyuan Hou1, Min Jiang4, Tiejun Zhang5, Gang Bai1.   

Abstract

BACKGROUND: Shufengjiedu Capsule (SFJD) is a type of Chinese traditional medicine compound for the treatment of acute upper respiratory tract infection. The present work aims to decipher the mechanism of SFJD.
METHODS: In this study, we used target prediction and RNA sequence (RNA-Seq) based on transcriptome analysis to clarify the inflammation-eliminating mechanism of SFJD. Firstly, Pseudomonas aeruginosa (PAK) was used to induce acute lung injury in KM mice. After being treated by SFJD, the differently expressed genes were analyzed by RNA-Seq. Secondly, the chemical constituents of SFJD were identified by ultra-performance liquid chromatography quadrupole/time of flight mass spectrometry (UPLC/Q-TOF-MS) and submitted to PharmMapper to predict targets. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and String 9.1 websites were employed to establish the interaction network of inflammation of these targets.
RESULTS: The results indicated that SFJD alleviated PAK induced lung injury in KM mice. We infer that the mechanism is a complex network containing 15 pathways related to inflammation regulated by 16 types of components from six types of herbs via 29 proteins. The ERK signaling pathway was a key pathway among them, which was predicted to be regulated by 14 types of components in SFJD. Phillyrin, emodin, and verbenalin were screened out by binding capacity, and the synergistic effect of them was further confirmed.
CONCLUSIONS: Various components of SFJD ameliorated PAK induced upper respiratory tract infection via multiple targets, of which ERK phosphorylation might be the key event regulated specifically by verbenalin, phillyrin and emodin.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ERK signaling pathway; Shufengjiedu capsule; Transcriptome analysis; UPLC/Q-TOF; Verbenalin

Mesh:

Substances:

Year:  2017        PMID: 28802227     DOI: 10.1016/j.biopha.2017.07.118

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

1.  Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Xiao-Wen Zhang; Ru-Yu Xia; Jia-Qi Gao; Jin-Jun Liu; De-Hao Xu; Xun Li; Xiao-Yang Hu; Merlin Willcox; Michael Moore; Meng-Yuan Dai; Jeanne Trill; Yu-Tong Fei; Jian-Ping Liu
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

2.  Shufeng Jiedu capsules protect rats against LPS-induced acute lung injury via activating NRF2-associated antioxidant pathway.

Authors:  Qingwu Liao; Wenan Chen; Zhufeng Tong; Mingming Xue; Tianwen Gu; Ying Yuan; Zhenju Song; Zhengang Tao
Journal:  Histol Histopathol       Date:  2020-12-21       Impact factor: 2.303

Review 3.  Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.

Authors:  Chang Li; Lin Wang; Linzhu Ren
Journal:  Virus Res       Date:  2020-06-24       Impact factor: 3.303

4.  Combining use of Phillyrin and autophagy blocker alleviates laryngeal squamous cell carcinoma via AMPK/mTOR/p70S6K signaling.

Authors:  Da-Hua Wang; Xi He; Qing He
Journal:  Biosci Rep       Date:  2019-06-20       Impact factor: 3.840

Review 5.  Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

Authors:  Hongbin Huang; Guigui Zhang; Yuquan Zhou; Chenru Lin; Suling Chen; Yutong Lin; Shangkang Mai; Zunnan Huang
Journal:  Front Chem       Date:  2018-05-09       Impact factor: 5.221

Review 6.  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.

Authors:  Wei Zhuang; Zheng Fan; Yanqi Chu; Haizheng Wang; Ying Yang; Li Wu; Nan Sun; Ge Sun; Yuqiao Shen; Xiaolan Lin; Guiming Guo; Shengyan Xi
Journal:  Front Pharmacol       Date:  2020-07-17       Impact factor: 5.810

Review 7.  Contribution of traditional Chinese medicine to the treatment of COVID-19.

Authors:  Wan-Ying Wang; Ying Xie; Hua Zhou; Liang Liu
Journal:  Phytomedicine       Date:  2020-07-07       Impact factor: 5.340

Review 8.  Current epidemiological and clinical features of COVID-19; a global perspective from China.

Authors:  Huilan Tu; Sheng Tu; Shiqi Gao; Anwen Shao; Jifang Sheng
Journal:  J Infect       Date:  2020-04-18       Impact factor: 38.637

9.  Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.

Authors:  Lu Xia; Yujing Shi; Jie Su; Thomas Friedemann; Zhenggang Tao; Yunfei Lu; Yun Ling; Ying Lv; Ronghua Zhao; Zihan Geng; Xiaolan Cui; Hongzhou Lu; Sven Schröder
Journal:  Phytomedicine       Date:  2020-10-22       Impact factor: 5.340

Review 10.  Pay attention to situation of SARS-CoV-2 and TCM advantages in treatment of novel coronavirus infection.

Authors:  Chang-Xiao Liu
Journal:  Chin Herb Med       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.